Design, synthesis and biological evaluation of mogrol derivatives as a novel class of AMPKα2β1γ1 activators

Bioorg Med Chem Lett. 2020 Jan 15;30(2):126790. doi: 10.1016/j.bmcl.2019.126790. Epub 2019 Nov 9.

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) has been considered as a promising drug target for its regulation in both glucose and lipid metabolism. Mogrol was originally identified from high throughput screening as a small molecule activator of AMPK subtype α2β1γ1. In order to enhance its potency on AMPK and summarize the structure-activity relationships, a series of mogrol derivatives were designed, synthesized and evaluated in pharmacological AMPK activation assays. The results showed that the amine derivatives at the 24-position can improve the potency. Among them, compounds 3 and 4 exhibited the best potency (EC50: 0.15 and 0.14 μM) which was 20 times more potent than mogrol (EC50: 3.0 μM).

Keywords: AMPK; AMPKα2β1γ1 activators; Mogrol derivatives; Structure-activity relationships.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / chemistry
  • AMP-Activated Protein Kinases / metabolism*
  • Allosteric Regulation / drug effects
  • Cucurbitaceae / chemistry
  • Cucurbitaceae / metabolism
  • Drug Design*
  • Enzyme Activators / chemical synthesis*
  • Enzyme Activators / metabolism
  • Enzyme Activators / pharmacology
  • Humans
  • Structure-Activity Relationship
  • Triterpenes / metabolism*
  • Triterpenes / pharmacology

Substances

  • Enzyme Activators
  • Triterpenes
  • AMP-Activated Protein Kinases